A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
Daiichi Sankyo Inc
The purpose of this research is to learn more about and investigational drug called raludotatug deruxtecan, hereafter referred to as D-DXd. it is being studies to see if it is effective, tolerable, and if your disease or medical condition improves while taking it.
Enrollment Form
This study is currently enrolling.